News
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...
GlobalData on MSN1d
JCR Pharma and Alexion partner on JUST-AAV gene therapy platformJCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...
GlobalData on MSN1d
Enrolment concludes in Beacon Therapeutics’ trial of laru-zova for XLRPBeacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova ...
JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...
CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...
Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...
The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback